Roja Asadpour - Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Negar Firouzabadi - Department of Pharmacology & Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
Ilnaz Yavarian - Department of Pharmacology, School of Pharmacy, Shiraz University of Medical Sciences, International Branch, Shiraz, Iran
Kamiar Zomoorodian - Department of Medical Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Ehsan Bahramali - Non communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran

Background and Aim : Pharmacogenetic has a proven role in the treatment of different illnesses as a patient with special genotype can have a better response to a specific drug. On the other hand, genetic factors contribute substantially to the likelihood of developing major depressive disorder (MDD). The importance of adrenergic system elements in cognition and behavior, and their involvement in etiology of depression imply that adrenergic receptors beta gene polymorphism(s) might also have an association with drug response, thus the aim of this study is evaluating the relationship between β1AR gene polymorphisms [ADRB1(G1165C)] and drug response.Methods : Among different antidepressants, we focused on fluoxetine as it is prescribed frequently in Iran and it belongs to one of the most efficient antidepressant categories with a minimum side effect. The presence of MDD was reconfirmed at study entry using DSM-V criteria. One hundred and one newly diagnosed patients were treated with fluoxetine for 6 weeks. Response to treatment was defined as a 50% decrease in Hamilton Rating Scale for Depression (HRSD). Genotyping of adrenergic system genes polymorphism was performed by PCR-RFLP method.Results : 57 patients (58.4%), were responders to fluoxetine (baseline HDRS: 26.1±10.2; HDRS after week 6: 11.1±7.5) and 44 patients (41.6%), were non-responders (baseline HDRS:26.3±9.5; HDRS after week 6: 21.9±9.5). Demographic data of patients are demonstrated in Table 2. Table 3 shows the genotype and allele frequencies of patients receiving fluoxetine based on a 50% score reduction. The frequencies of all Patients carrying different genotypes have been calculated. Statistical analysis of responsive and non-responsive genotypes demonstrated that there is no significant relationship between β1AR polymorphism and the patient’s response to fluoxetine (P=0.905; OR=0.714; 95%CI=0.095-5.159).Conclusion : Our results demonstrated that there is no significant relationship between β1AR polymorphism and the patient’s response to fluoxetine.

major depressive disorders; adrenergic system; fluoxetine; genetic polymorphism; pharmacogenetic